SGLT2
SGLT2 (SLC5A2) is a renal sodium-glucose cotransporter that mediates glucose reabsorption in the early proximal tubule and accounts for most kidney glucose reabsorption[1]. Mechanistically, renal glucose handling depends on coordinated SGLT2, SGLT1, and GLUT2 transport, linking filtered glucose recovery to sodium-coupled epithelial transport[2]. In Sglt2 knockout mice, reduced proximal tubular glucose reabsorption produced a glucosuric phenotype that models human SLC5A2-associated renal glucosuria[1]. Compared with SGLT1, SGLT2 shows low-affinity, high-capacity transport in the early proximal tubule, whereas SGLT1 provides higher-affinity, lower-capacity transport for remaining luminal glucose[2]. Therefore, SGLT2 inhibitors provide experimental tools to block renal glucose reabsorption and investigate hyperglycemia, diabetic kidney physiology, and cardiorenal outcomes[3][4][5].- Empagliflozin reduced cardiovascular death in high-risk type 2 diabetes clinical trials[4]. - Dapagliflozin reduced kidney disease progression or cardiovascular death in chronic kidney disease[5].
References:
- [1]. Vallon V, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011 Jan;22(1):104-12. [Content Brief]
- [2]. Ghezzi C, et al. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018 Oct;61(10):2087-2097. [Content Brief]
- [3]. Vallon V, et al. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017 Feb;60(2):215-225. [Content Brief]
- [4]. Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. [Content Brief]
- [5]. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. [Content Brief]
All Product Categories
-
SGLT2 Related Products (67)
Related Products (67)
-
Phlorizin (Standard)
0 ImagesPhlorizin (Floridzin) (Standard) is the analytical standard of Phlorizin. This product is intended for research and analytical applications. Phlorizin is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities.
-
TP0438836
0 ImagesCat. No.: HY-124664CAS No.: 957772-01-9TP0438836 (compound 30b) is a SGLT1 inhibitor, with IC50 values of 28 nM and 7 nM for hSGLT1 and hSGLT2, respectively. TP0438836 can be used in diabetes research.
-
Dapagliflozin-d4
0 ImagesCat. No.: HY-10450S2CAS No.: 1224234-25-6Synonyms: BMS-512148-d4Dapagliflozin-d4 (BMS-512148-d4) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
-
Sergliflozin-A
0 ImagesCat. No.: HY-165438CAS No.: 360775-96-8Sergliflozin-A is a compound used to inhibit type 2 diabetes. It can inhibit glucose transporters in the kidney, competitively inhibit hSGLT1 and hSGLT2, and mutations at different sites have different effects on its inhibitory effect.
-
galacto-Dapagliflozin
0 ImagesCat. No.: HY-137145CAS No.: 1408245-02-2Galacto-dapagliflozin is a selective inhibitor for hSGLT2 with Ki of 25 nM.
-
SGLT2-IN-4
0 ImagesCat. No.: HY-180201CAS No.: 1061314-92-8SGLT2-IN-4 (Compound 1) is a selective and orally active sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor. SGLT2-IN-4 can increase the proportion of protein α-helix and enhance the stability of the SGLT2-D201A mutant. SGLT2-IN-4 can be used for the research of type 2 diabetes.
